{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'The Total Ocular Symptom Score (TOSS) will be calculated using the 3 eye-related non-nasal', 'symptoms: itching/burning eyes, tearing/watering eyes, and redness of eyes.', '10.3.', 'Physician Assessment of Nasal Symptom Severity', 'The Physician Assessment of Nasal Symptom score (PNSS) will be derived from the intensity of', 'the following nasal symptoms associated with AR: rhinorrhea (runny nose), nasal congestion,', 'nasal itching, and sneezing; each of these symptoms will be assessed as described in Section 10.2', '(Raphael et al, 2013). Investigators will assess the severity of these symptoms based on', 'questioning the subjects (overall feeling since last visit), the ear nose and throat (ENT)', 'examination, and other observations by the Investigator.', 'Whenever possible, the same medically qualified person should complete this assessment for the', \"same subject throughout the subject's participation in this study.\", '10.4.', 'Pediatric Rhinoconjuntivitis Quality of Life Questionnaire (PRQLQ)', 'The PRQLQ (Appendix 3) used in this study is a validated, disease-specific, quality-of-life', '(QOL) questionnaire developed to measure the physical, emotional, and social impairments that', 'are experienced by children (aged >6 to <12 years) with rhinoconjunctivitis (Juniper et al, 1998).', 'The PRQLQ has 23 questions in 5 domains (nose symptoms, eye symptoms, practical problems,', 'activity limitation and other symptoms) (Juniper et al, 1998). Subjects recall how they have been', 'during the previous week and respond to each question on a 7-point scale. The overall PRQLQ', 'score is the mean of all 23 responses and the individual domain scores are the means of the items', 'in those domains.', 'The interviewer-administered PRQLQ will be provided to subjects at the investigational site at', 'the Randomization Visit (Visit 2) and the Final Visit/Discontinuation Visit (Visit 4). The', 'PRQLQ administration must be the first procedure conducted at these study visits.', 'The study site personnel and the Investigators will be provided with detailed instructions about', 'conducting QOL assessments in order to achieve maximum compliance with the standards of', 'QOL assessments in a clinical study environment and to maximize data quality. Clinical staff', 'must ask the questions exactly as worded in the questionnaire. Words should not be simplified,', 'skipped or changed. Above all, clinical staff should never attempt to paraphrase or revise the', 'questions. After completion of the PRQLQ, the site personnel will check the questionnaire for', 'completeness and legibility.', 'An English version of the PRQLQ will be provided to all subjects who provide informed', 'consent/assent in English. However, if a subject consents/assents in a language other than', 'English, the PRQLQ will be provided to the subject in that language provided a validated version', 'of the PRQLQ is available in that language. If a validated version of the PRQLQ is not available', 'in that language, then the subject will be exempt from completing the PRQLQ.', 'Glenmark', 'CONFIDENTIAL', 'Page 46 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '11.', 'ASSESSMENT OF SAFETY', '11.1.', 'Safety Parameters', 'Safety assessments will consist of monitoring and recording all AEs (including severity as mild,', 'moderate or severe as per Section 11.2) and SAEs; periodic measurements of vital signs, ENT', 'examinations, and physical examinations as detailed in the Schedule of Procedures and', 'Assessments (Table 2). Additional details for the safety procedures performed in the study are', 'detailed below.', 'Safety assessments (eg, vital signs measurements), including those that worsen from baseline,', 'that are considered to be clinically significant in the medical and scientific judgment of the', 'Investigator will be recorded as AEs or SAEs. If a repeat safety or other physical assessment is', 'performed by the Investigator, those results should be entered in the eCRF as an unscheduled', 'assessment.', 'However, any clinically significant safety assessments that are associated with the underlying', \"disease, unless judged by the Investigator to be more severe than expected for the subject's\", 'condition, will not be reported as AEs or SAEs.', '11.1.1.', 'Demography', 'Subject demographic information will be collected at the Screening Visit (Visit 1). Demographic', 'information includes date of birth (or age), sex, race/ethnicity, and any other study-specific', 'demography.', '11.1.2.', 'Baseline Assessments', '11.1.2.1. Medical History and Physical Examinations', 'Medical and surgical history, current medical conditions, and allergen testing data (skin prick', 'test for relevant allergen, if required), will be recorded at the Screening Visit (Visit 1). All', 'relevant medical and surgical history within 2 years must be noted in the Medical and Surgical', 'History or equivalent CRF/eCRF.', '11.1.3.', 'Vital Signs', 'Vital sign evaluations will be performed as designated in the Schedule of Procedures and', 'Assessments (Table 2). Vital sign evaluations will include sitting blood pressure (mm Hg) and', 'pulse rate (beats/minute) after at least 5 minutes of rest in the seated position. Either an', 'electronic or a manual sphygmomanometer may be used. For each subject, blood pressure', 'measurements will be taken from the same arm throughout the study, if possible. Pulse rate will', 'be measured from the radial pulse counted electronically or manually over at least 15 seconds,', 'adjusted per minute. The methods of assessment should be consistent throughout the study for', 'each subject. A medically qualified staff member will perform the vital sign evaluations. If a', 'clinically important change in vital signs is observed, the assessment should be repeated in 5 to', '10 minutes to confirm the change.', 'Glenmark', 'CONFIDENTIAL', 'Page 47 of 90']\n\n###\n\n", "completion": "END"}